Molecule
Perampanel is a noncompetitive AMPA glutamate receptor antagonist indicated for treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older, among other approved uses. MedsAcross supplies Perampanel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older. Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older
Source: US FDA prescribing information
Perampanel is a non-competitive antagonist of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor on post-synaptic neurons. Glutamate is the primary excitatory neurotransmitter in the central nervous system and is implicated in a number of neurological disorders caused by neuronal over excitation. The precise mechanism by which FYCOMPA exerts its antiepileptic effects in humans is unknown.
Source: US FDA prescribing information
Dosing in the absence of moderate or strong CYP3A4 inducers Starting dose: 2 mg once daily orally at bedtime. May increase dose based on clinical response and tolerability by increments of 2 mg once daily no more frequently than at weekly intervals. Recommended maintenance dose in monotherapy or adjunctive therapy for partial-onset seizures: 8 mg to 12 mg once daily at bedtime. Recommended maintenance dose in adjunctive therapy for primary generalized tonic-clonic seizures: 8 mg once daily at bedtime. Measure oral suspension using provided adaptor and dosing syringe. Dosing in the presence of concomitant moderate or strong CYP3A4 inducers: see section
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Boxed warning (serious psychiatric and behavioral reactions): Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA. Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior. Neurologic Effects: Monitor for dizziness, gait disturbance, somnolence, and fatigue. Patients should use caution when driving or operating machinery. Falls: Monitor for falls and injuries. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/ Multi-Organ Hypersensitivity: Discontinue if no alternate etiology. Withdrawal of Antiepileptic Drugs: In patients with epilepsy, there may be an increase in seizure frequency
Source: US FDA prescribing information
The following serious adverse reactions are described below and elsewhere in the labeling: Serious Psychiatric and Behavioral Reactions Suicidal Behavior and Ideation Neurologic Effects Falls Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Most common adverse reactions (≥5% and ≥1% higher than placebo) include dizziness, somnolence, fatigue, irritability, falls, nausea, weight gain, vertigo, ataxia, headache, vomiting, contusion, abdominal pain, and anxiety
Source: US FDA prescribing information
Contraceptives: 12 mg once daily may decrease the effectiveness of hormonal contraceptives containing levonorgestrel. Moderate and Strong CYP3A4 Inducers (including carbamazepine, oxcarbazepine, and phenytoin): increase clearance of perampanel and decrease perampanel plasma concentrations. When moderate or strong CYP3A4 inducers are introduced or withdrawn, monitor patients closely. Dose adjustment of FYCOMPA may be necessary
Source: US FDA prescribing information
Storage Tablets: store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Oral Suspension: Do not store above 30°C (86°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
14 presentations of Perampanel, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Perampanel 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Perampanel 12 mg tabletOralGeneric name | — | US FDA | Available on request |
| Perampanel 2 mg tabletOralGeneric name | — | US FDA | Available on request |
| Perampanel 4 mg tabletOralGeneric name | — | US FDA | Available on request |
| Perampanel 6 mg tabletOralGeneric name | — | US FDA | Available on request |
| Perampanel 8 mg tabletOralGeneric name | — | US FDA | Available on request |
| Fycompa 10 mg tabletOral | Catalyst Pharmaceuticals | US FDA | Available on request |
| Fycompa 12 mg tabletOral | Catalyst Pharmaceuticals | US FDA | Available on request |
| Fycompa 2 mg tabletOral | Catalyst Pharmaceuticals | US FDA | Available on request |
| Fycompa 4 mg tabletOral | Catalyst Pharmaceuticals | US FDA | Available on request |
| Fycompa 6 mg tabletOral | Catalyst Pharmaceuticals | US FDA | Available on request |
| Fycompa 8 mg tabletOral | Catalyst Pharmaceuticals | US FDA | Available on request |
| Fycompa 0.5 mg/mL oral suspensionOral | Catalyst Pharmaceuticals | US FDA | Available on request |
| Perampanel 0.5 mg/mL oral suspensionOralGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Perampanel in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 14 presentations of Perampanel and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Perampanel, including Fycompa.
Yes. The US FDA first approved Perampanel on 22 October 2012, according to Drugs@FDA.
Yes. Perampanel has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Perampanel is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Perampanel is classified under ATC code N03AX22 (Perampanel).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.